home / stock / abbv / abbv quote
Last: | $166.41 |
---|---|
Change Percent: | -0.22% |
Open: | $165.02 |
Close: | $166.41 |
High: | $166.6 |
Low: | $163.25 |
Volume: | 5,526,776 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$166.41 | $165.02 | $166.41 | $166.6 | $163.25 | 5,526,776 | 04-19-2024 |
$164.66 | $164.96 | $164.66 | $167.44 | $164.43 | 4,480,224 | 04-18-2024 |
$164.25 | $164.15 | $164.25 | $164.74 | $163.23 | 4,792,382 | 04-17-2024 |
$162.54 | $162.18 | $162.54 | $163.74 | $162.0772 | 4,881,516 | 04-16-2024 |
$161.67 | $164.52 | $161.67 | $164.7 | $161.5 | 5,433,730 | 04-15-2024 |
$162.28 | $164.45 | $162.28 | $164.45 | $160 | 7,029,475 | 04-12-2024 |
$167.52 | $169.2 | $167.52 | $169.37 | $167.227 | 3,307,034 | 04-11-2024 |
$169.03 | $168.59 | $169.03 | $169.96 | $167.36 | 3,231,664 | 04-10-2024 |
$170.14 | $169.73 | $170.14 | $170.545 | $167.395 | 5,933,987 | 04-09-2024 |
$169.8 | $169.21 | $169.8 | $171.97 | $168.4 | 4,744,996 | 04-08-2024 |
$170 | $168 | $170 | $171.04 | $167.29 | 7,030,108 | 04-05-2024 |
$167.9 | $177.65 | $167.9 | $177.7 | $167.45 | 10,538,991 | 04-04-2024 |
$177.33 | $180.72 | $177.33 | $181.6 | $176.6 | 5,892,990 | 04-03-2024 |
$180.69 | $179.39 | $180.69 | $181.03 | $178.51 | 4,523,931 | 04-02-2024 |
$180.76 | $181.88 | $180.76 | $181.9 | $179.24 | 3,502,141 | 04-01-2024 |
$182.1 | $181 | $182.1 | $182.3 | $180.3 | 5,418,687 | 03-29-2024 |
$182.1 | $181 | $182.1 | $182.3 | $180.3 | 5,418,687 | 03-28-2024 |
$180.35 | $179.8 | $180.35 | $180.58 | $178.81 | 5,073,508 | 03-27-2024 |
$179.19 | $179.23 | $179.19 | $179.77 | $178.38 | 4,392,427 | 03-26-2024 |
$178.53 | $179 | $178.53 | $179.2 | $178.125 | 4,366,502 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis PR Newswire − Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib...
On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc’s (NYSE:ABB...